Please login or sign up to post and edit reviews.
Will Merck's new anti-viral drug help fight COVID-19? | In Focus
Publisher |
The Hindu
Media Type |
audio
Podknife tags |
India
News & Politics
Categories Via RSS |
News
News Commentary
Publication Date |
Oct 27, 2021
Episode Duration |
00:19:29
The new anti-viral drug brought out by Merck Pharmaceuticals, Molnupiravir, seems to be a promising development in the global fight against COVID-19. Early results from the phase-3 trial of the drug report that it halves the chances of hospitalisation in patients with mild to moderate COVID-19. It is also an oral medication -- it can be taken in pill form, unlike other anti-viral drugs that have to administered intravenously, usually in a hospital setting. Merck has now applied for emergency use authorisation for its drug in the United States. It has also, meanwhile, tied up with eight Indian drugmakers for the manufacture of molunupiravir. How does this drug work? Will it become a significant tool to combat COVID-19, which continues to kill people both in India and abroad? Will it accessible and easily available to those who need it? Guest:  Dr. Satyajit Rath, adjunct professor at the Indian Institute of Science Education and Research, Pune Host: Zubeda Hamid

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review